Wan Tai Biology: Recombinant Respiratory Syncytial Virus Vaccine Receives Clinical Trial Approval Notification

Wan Tai Biology announced that its wholly-owned subsidiary, Xiamen Wan Tai Canghai Biotechnology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the recombinant respiratory syncytial virus vaccine. The product is called recombinant respiratory syncytial virus vaccine, with a dosage of 0.5ml per dose after reconstitution, in injectable form, used to prevent lower respiratory tract diseases caused by respiratory syncytial virus infection.